Silence Therapeutics Corp (SLN) - Market Value to Book Value Ratio
The Silence Therapeutics (SLN) price chart reflects the dynamics of a company developing innovative DNA-based medicines. The business relies on strategic alliances with global pharma behemoths to bring drugs for cardiac and hematological pathologies to market, with the metric standing at 24.33. Production capacities are distributed between Europe and the US, while the brand's scientific prestige in the siRNA field is confirmed by successful clinical trials.
Summary analytical data breakdowns for Silence Therapeutics PLC (SLN)
- share price and expert price forecast:
- market capitalization indicators:
- book capitalization data:
- debt and solvency information:
Total Debt to Capital Silence Therapeutics|SLN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Silence Therapeutics Inc.|SLN - Company Debts|Debts to Book Capitalization Silence Therapeutics Inc.|SLN - Long-Term Debt|Company Short-Term Debt Silence Therapeutics|Quick Ratio silence-therapeutics.com
- earnings and valuation multiples indicators:
Fundamental valuation:Silence Therapeutics - SLN
For an investor, evaluating Silence Therapeutics (SLN) requires analyzing the gap between market expectations and the biotech's actual assets. By analyzing the price-to-book ratio trend, we determine the equity overvaluation coefficient relative to net assets, which is critical for companies with a minimal operational footprint and standard eco-expenses for bio-waste disposal that define the balance sheet base.
Analysis of competing companies
TEM: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio QGEN|Market Value to Book Value Ratio Ionis|Capitalization to Book Value Ratio RGEN (Repligen Corp)|Market Capitalization to Book Value Ratio RNA|Market Capitalization to Book Value Ratio CRISPR (CRSP)|Market Value to Book Value Ratio GeneDx Holdings Corp. WGS|Market Capitalization to Book Value ultragenyx.com (RARE)|Beam Therapeutics - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Sarepta Therapeutics SRPT|Twist Bio (TWST) - Market Value to Book Value Ratio|TXG (10x) - Market Value to Book Value Ratio|NTLA (Intellia Therapeutics) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio stoketherapeutics.com STOK|Market Value to Book Value Ratio BioLife Solutions (BLFS)|Wave Life Sciences Ltd - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio MAZE (Maze Tx)|SION - Market Cap to Net Assets Ratio|Prime Medicine, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio tayshagtx.com|QURE (uniQure) - Market Cap to Net Assets Ratio|MeiraGTx Holdings - Market Value to Book Value|Market Cap to Net Assets Ratio RGNX|SLDB (Solid Corp) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio OCGN|PACB (pacb.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio BNTC (Benitec Biopharma)|Design Therapeutics Inc (DSGN) - Market-to-Book Ratio|RCKT - Market Value to Book Value Ratio|Market Value to Book Value FDMT (4D Molecular Corp)|LXEO: Market Capitalization to Book Value Ratio|Korro Bio (KRRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Editas Medicine|ProQR Therapeutics NV - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio CDXS|SGMO - Market-to-Book Ratio|Nautilus Bio - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio metagenomi.co MGX|DTIL: Market Cap to Net Assets Ratio|Generation Bio Co. - Market Cap to Book Value Multiple|BOLD: Market Capitalization to Book Value Ratio|XCUR - Market Capitalization to Book Value|IMNN (Imunon Inc) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio RXi Pharmaceuticals (PHIO)|Market Value to Book Value Ratio Mustang Bio, Inc. (MBIO)|Market Capitalization to Book Value transcodetherapeutics.com|Market Value to Book Value Ratio Bionano Genomics BNGO|Market Capitalization to Book Value Applied DNA Corp (APDN)|BLUE - Market Value to Book Value Ratio|IPA: Market Value to Book Value Ratio|Omega Therapeutics, Inc. (OMGA) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio OMIC|RGLS (Regulus Therapeutics Inc) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio SYRS (Syros Pharmaceuticals, Inc)|Market Value to Book Value Ratio Telesis Bio, Inc. (TBIO)|traconpharma.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio UBX (Unity Biotechnology, Inc.)